In:
International Journal of Cancer, Wiley, Vol. 119, No. 10 ( 2006-11-15), p. 2476-2480
Abstract:
The clonotypic T‐cell receptor (TCR) is a potential target antigen for specific immunotherapy of cutaneous T‐cell lymphoma (CTCL). We identified T‐cell epitopes from the rearranged TCR β chain of the malignant T‐cell population by the “reverse immunology” approach. Peptide‐specific T‐cell lines were generated against predicted epitopes and tested for the recognition of tumor cells and cells transfected with the full‐length DNA coding for TCRV β chain. Two peptides derived from the clonotypic TCRVβ of a HLA‐A2 positive patient could induce peptide‐specific T cells from peripheral blood mononuclear cells of healthy donors and the patient as assessed by IFN‐γ ELISpot assay. Furthermore, the reactive CTLs efficiently recognized autologous Sézary tumor cells, as well as HLA‐A2 positive 293 cells transfected with recombinant plasmid expressing the corresponding TCRVβ29 protein. Similar results were obtained in a HLA‐A3+ patient for TCRVβ7‐Jβ2.7. In conclusion, our experiments show that the TCR β chain harbors epitopes suitable as targets for specific vaccination which might be a promising approach for the specific immunotherapy of cutaneous T‐cell lymphoma patients. © 2006 Wiley‐Liss, Inc.
Type of Medium:
Online Resource
ISSN:
0020-7136
,
1097-0215
Language:
English
Publisher:
Wiley
Publication Date:
2006
detail.hit.zdb_id:
218257-9
detail.hit.zdb_id:
1474822-8
Permalink